CAPSTAN
Research type
Research Study
Full title
A Retrospective Non-Interventional Study on First Line Treatment for Patients with BRAFV600E Mutant Metastatic Colorectal Cancer (mCRC)
IRAS ID
278356
Contact name
Harpreet Singh Wasan
Contact email
Sponsor organisation
Pierre Fabre
Duration of Study in the UK
0 years, 5 months, 30 days
Research summary
How are metastasic colorectal cancer patients with BRAF V600E mutation currently treated, and what are the outcomes?
CAPSTAN is a non-interventional retrospective study. The purpose of this study is to describe how patients with a Mutant Metastatic Colorectal Cancer that may have a genetic origin (BRAF V600E mutation) were treated and the related outcomes during their treatment between January 1st, 2016 and December 31st, 2018. Every patient who received first line treatment for mCRC mutant BRAF during this period is eligible.
This study will be conducted on medical records data. Data will be extracted for the period between the January 1st, 2016 and the January 31st, 2020. Patients will not directly contribute to this study.
About 300 patients will be included worldwide from 62 centres. Around 49 patients will be included by 9 sites across the UK.REC name
East Midlands - Nottingham 1 Research Ethics Committee
REC reference
20/EM/0207
Date of REC Opinion
10 Aug 2020
REC opinion
Favourable Opinion